Skip to main content

Featured

How to Grocery Shop for a Family of 4 Under $300/Month in Ontario (2026 Guide)

Published: April 2026 | Reading time: 10 min | Category: Money Saving Tips, Budgeting, Saving Money Grocery prices in Ontario have been brutal. The average Canadian family of four is now spending $1,200–$1,400 per month on food according to recent food price reports — and many families are spending even more without realizing it. But here's the truth: feeding a family of four well in Ontario for under $300/month is absolutely possible. It requires planning, a few smart habits, and knowing exactly which stores, apps, and strategies to use. Families across Ontario are doing it right now. This guide shows you exactly how — with a real meal plan, a real shopping strategy, and real stores to use in 2026. Is $300/Month for a Family of 4 Actually Realistic? Yes — with conditions. Here's what it requires: Cooking most meals at home (no takeout budget included) Meal planning weekly before you shop Shopping at discount grocery stores, not full-price chains Using flyer apps and loy...
Post a Comment
Read more

article

Labels

Alzheimer’s Drug Donanemab Receives FDA Advisers’ Endorsement for Slowing Disease Progression

 

A significant milestone has been reached in the fight against Alzheimer’s disease. Eli Lilly’s closely watched Alzheimer’s drug, donanemab, has won the unanimous backing of federal health advisers. The drug is specifically intended for people with mild dementia caused by this brain-robbing disease.

The decision by the Food and Drug Administration (FDA) advisers comes after careful consideration of the drug’s benefits and risks. Donanemab has demonstrated the ability to modestly slow cognitive decline and memory problems associated with Alzheimer’s. Although it’s not a cure, this endorsement represents a promising step forward in managing the disease.

Here are the key points:

  1. Effectiveness: Donanemab has shown effectiveness in slowing cognitive decline. Patients who received monthly intravenous infusions of the drug declined about 35% more slowly than those who received a placebo.
  2. Risk Assessment: The FDA panel weighed the risks, including side effects like brain swelling and bleeding, which will need monitoring. Despite these risks, the panel concluded that the drug’s benefits outweighed them.
  3. Tau Protein Screening: Unlike previous concerns about tau protein screening, most panelists believed there was enough evidence to prescribe the drug broadly without requiring such screening.
  4. FDA Decision: The FDA will make the final decision on approval later this year. If approved, donanemab would become only the second Alzheimer’s drug in the U.S. shown to convincingly slow cognitive decline.

This endorsement brings hope to individuals and families affected by Alzheimer’s, and we eagerly await the FDA’s final decision. Stay tuned for further updates on this groundbreaking development! 

Labels:

Comments

Post a Comment